title: Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.
abstract: As survival rates in allogeneic hematopoietic stem cell transplantation (HSCT) continue to improve, attention to long-term complications, including cardiovascular disease, becomes a major concern. Cardiovascular disease and dyslipidemia are a common, yet often overlooked occurrence post-HSCT that results in significant morbidity and mortality. Also, increasing evidence shows that several anti-hyperlipidemia medications, the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in particular, may have a role in modulating graft-versus-host disease (GVHD). However, factors such as drug-drug interactions, adverse effect profiles, and the relative efficacy in lowering cholesterol and triglyceride levels must be taken into account when choosing safe and effective lipid-lowering therapy in this setting. This review seeks to provide guidance to the clinician in the management of dyslipidemia in the allogeneic HSCT population, taking into account the recently published American College of Cardiology/American Heart Association guidelines on hyperlipidemia management, special considerations in this challenging population, and the evidence for each agent's potential role in modulating GVHD.
authors.affiliation: Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan. Electronic address: bernardmarini@gmail.com.
authors.forename: Bernard Lawrence
authors.initials: BL
authors.lastname: Marini
authors.affiliation: Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan.
authors.forename: Sung Won
authors.initials: SW
authors.lastname: Choi
authors.affiliation: Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan.
authors.forename: Craig Alan
authors.initials: CA
authors.lastname: Byersdorfer
authors.affiliation: Department of Pharmacy, Karmanos Cancer Institute, Detroit, Michigan.
authors.forename: Simon
authors.initials: S
authors.lastname: Cronin
authors.affiliation: Department of Pharmacy Services and Clinical Sciences, University of Michigan Health System and College of Pharmacy, Ann Arbor, Michigan.
authors.forename: David G
authors.initials: DG
authors.lastname: Frame
mesh_terms: D064591:Allografts; D004347:Drug Interactions; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006086:Graft vs Host Disease / Q000097:blood / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Allogeneic transplantation; Dyslipidemia; Graft-versus-host disease; Late complications; Statins